Nexentis Technologies (NXTS) said Monday its subsidiary, MitoCareX Bio, has entered into an engagement with Boltz, an AI research lab, to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier proteins of interest to MitoCareX's pipeline.

Shares jumped over 200% as trading volume catapulted to over 55 million from a daily average of about 208,000.

AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash for a total equity value of $10.9 billion, the companies said Monday.

Shares of Apogee soared 47%, with intraday trading volume of over 47.1 million against a daily average of about 975,000.

Definium Therapeutics (DFTX) reported positive topline results from a phase 3 Emerge study of DT120 orally disintegrating tablet in major depressive disorder.

RBC Capital raised its price target to $57 from $36, while maintaining its outperform rating.

Shares surged 52% amid a jump in intraday trading volume to over 16 million from a daily average of roughly 1.9 million.

Price: 15.55, Change: +10.47, Percent Change: +206.08